factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 65-67 | 65-67 | T14 | in | COEXISTS_WITH | 65 | 67 | preserve | 56-64 | 56-64 | T6 | syndrome | DiseaseOrSyndrome | 56 | 64 | preserve | 84-96 | 84-96 | T8 | inflammation | PathologicFunction | 84 | 96 | A8 | Asthma is a complex syndrome in which bronchial inflammation and smooth muscle hyperactivity lead to labile airflow obstruction. | 36-170 | 36 | 170 | Asthma is a complex @SUBJECT$ @PREDICAT$ which bronchial @OBJECT$ and smooth muscle hyperactivity lead to labile airflow obstruction. |
Fact | preserve | 1220-1243 | 1234-1243 | T89 | inhaler treatment | USES | 1,220 | 1,243 | preserve | 1234-1243 | 1234-1243 | T87 | treatment | TherapeuticOrPreventiveProcedure | 1,234 | 1,243 | preserve | 1220-1227 | 1220-1227 | T86 | inhaler | MedicalDevice | 1,220 | 1,227 | A9 | Association with high IgE levels was limited to the interval flanked by D11S1335 and CD20 in a 0.8-Mb interval and was greatest for variants of Fc epsilonRIbeta and HTm4; these variants also associated with asthma (recurrent wheeze with labile airflow obstruction and need for regular inhaler treatment). | 917-1245 | 917 | 1,245 | Association with high IgE levels was limited to the interval flanked by D11S1335 and CD20 in a 0.8-Mb interval and was greatest for variants of Fc epsilonRIbeta and HTm4; these variants also associated with asthma (recurrent wheeze with labile airflow obstruction and need for regular @OBJECT$ @PREDICAT$ @SUBJECT$ ). |
Fact | preserve | 74-96 | 84-96 | T13 | bronchial inflammation | LOCATION_OF | 74 | 96 | preserve | 74-83 | 74-83 | T7 | bronchial | BodyPartOrganOrOrganComponent | 74 | 83 | preserve | 84-96 | 84-96 | T8 | inflammation | PathologicFunction | 84 | 96 | A10 | Asthma is a complex syndrome in which bronchial inflammation and smooth muscle hyperactivity lead to labile airflow obstruction. | 36-170 | 36 | 170 | Asthma is a complex syndrome in which @SUBJECT$ @PREDICAT$ @OBJECT$ and smooth muscle hyperactivity lead to labile airflow obstruction. |
Fact | preserve | 1643-1645 | 1643-1645 | T101 | in | TREATS | 1,643 | 1,645 | preserve | 1633-1642 | 1633-1642 | T95 | metformin | OrganicChemical | 1,633 | 1,642 | preserve | 1646-1654 | 1646-1654 | T96 | patients | PatientOrDisabledGroup | 1,646 | 1,654 | A1 | The study also found an extensive use of metformin in patients with contraindications and at highest risk of developing lactic acidosis. | 1586-1734 | 1,586 | 1,734 | The study also found an extensive use of @SUBJECT$ @PREDICAT$ @OBJECT$ with contraindications and at highest risk of developing lactic acidosis. |
Fact | preserve | 1411-1416 | 1411-1416 | T91 | using | ADMINISTERED_TO | 1,411 | 1,416 | preserve | 1417-1430 | 1417-1430 | T80 | glibenclamide | OrganicChemical | 1,417 | 1,430 | preserve | 1402-1410 | 1402-1410 | T79 | patients | PatientOrDisabledGroup | 1,402 | 1,410 | A4 | Of the 45 patients using glibenclamide, 40 (88.9%) had one or more risk factors for hypoglycaemia: over 65 years of age, renal impairment, or cognitive impairment and living alone. | 1392-1585 | 1,392 | 1,585 | Of the 45 @OBJECT$ @PREDICAT$ @SUBJECT$ , 40 (88.9%) had one or more risk factors for hypoglycaemia: over 65 years of age, renal impairment, or cognitive impairment and living alone. |
Fact | preserve | 2189-2191 | 2189-2191 | T131 | in | TREATS | 2,189 | 2,191 | preserve | 2161-2170 | 2161-2170 | T123 | metformin | OrganicChemical | 2,161 | 2,170 | preserve | 2192-2207 | 2199-2207 | T125 | type 2 diabetes | DiseaseOrSyndrome | 2,192 | 2,207 | A5 | CONCLUSIONS: There was evidence of over-utilization of metformin and glibenclamide in type 2 diabetes patients most at risk of adverse reactions. | 2100-2257 | 2,100 | 2,257 | CONCLUSIONS: There was evidence of over-utilization of @SUBJECT$ and glibenclamide @PREDICAT$ @OBJECT$ patients most at risk of adverse reactions. |
Fact | preserve | 82-85 | 82-85 | T8 | for | TREATS | 82 | 85 | preserve | 76-81 | 76-81 | T4 | drugs | PharmacologicSubstance | 76 | 81 | preserve | 86-101 | 93-101 | T5 | type 2 diabetes | DiseaseOrSyndrome | 86 | 101 | A6 | BACKGROUND: Commonly used drugs for type 2 diabetes are not ideal. | 50-116 | 50 | 116 | BACKGROUND: Commonly used @SUBJECT$ @PREDICAT$ @OBJECT$ are not ideal. |
Fact | preserve | 482-484 | 482-484 | T36 | in | TREATS | 482 | 484 | preserve | 454-467 | 454-467 | T28 | glibenclamide | OrganicChemical | 454 | 467 | preserve | 489-496 | 489-496 | T30 | elderly | AgeGroup | 489 | 496 | A7 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and metformin in the elderly and patients where published contraindications are present. | 292-562 | 292 | 562 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of @SUBJECT$ and metformin @PREDICAT$ the @OBJECT$ and patients where published contraindications are present. |
Fact | preserve | 2192-2216 | 2208-2216 | T130 | type 2 diabetes patients | PROCESS_OF | 2,192 | 2,216 | preserve | 2192-2207 | 2199-2207 | T125 | type 2 diabetes | DiseaseOrSyndrome | 2,192 | 2,207 | preserve | 2208-2216 | 2208-2216 | T126 | patients | PatientOrDisabledGroup | 2,208 | 2,216 | A8 | CONCLUSIONS: There was evidence of over-utilization of metformin and glibenclamide in type 2 diabetes patients most at risk of adverse reactions. | 2100-2257 | 2,100 | 2,257 | CONCLUSIONS: There was evidence of over-utilization of metformin and glibenclamide in @SUBJECT$ @PREDICAT$ @OBJECT$ most at risk of adverse reactions. |
Fact | preserve | 482-484 | 482-484 | T36 | in | TREATS | 482 | 484 | preserve | 454-467 | 454-467 | T28 | glibenclamide | OrganicChemical | 454 | 467 | preserve | 501-509 | 501-509 | T31 | patients | PatientOrDisabledGroup | 501 | 509 | A9 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and metformin in the elderly and patients where published contraindications are present. | 292-562 | 292 | 562 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of @SUBJECT$ and metformin @PREDICAT$ the elderly and @OBJECT$ where published contraindications are present. |
Fact | preserve | 311-321 | 311-321 | T34 | management | TREATS | 311 | 321 | preserve | 472-481 | 472-481 | T29 | metformin | OrganicChemical | 472 | 481 | preserve | 325-340 | 332-340 | T22 | type 2 diabetes | DiseaseOrSyndrome | 325 | 340 | A11 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and metformin in the elderly and patients where published contraindications are present. | 292-562 | 292 | 562 | AIM: To review the @PREDICAT$ of @OBJECT$ at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and @SUBJECT$ in the elderly and patients where published contraindications are present. |
Fact | preserve | 2189-2191 | 2189-2191 | T131 | in | TREATS | 2,189 | 2,191 | preserve | 2175-2188 | 2175-2188 | T124 | glibenclamide | OrganicChemical | 2,175 | 2,188 | preserve | 2208-2216 | 2208-2216 | T126 | patients | PatientOrDisabledGroup | 2,208 | 2,216 | A13 | CONCLUSIONS: There was evidence of over-utilization of metformin and glibenclamide in type 2 diabetes patients most at risk of adverse reactions. | 2100-2257 | 2,100 | 2,257 | CONCLUSIONS: There was evidence of over-utilization of metformin and @SUBJECT$ @PREDICAT$ type 2 diabetes @OBJECT$ most at risk of adverse reactions. |
Fact | preserve | 482-484 | 482-484 | T36 | in | TREATS | 482 | 484 | preserve | 472-481 | 472-481 | T29 | metformin | OrganicChemical | 472 | 481 | preserve | 501-509 | 501-509 | T31 | patients | PatientOrDisabledGroup | 501 | 509 | A14 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and metformin in the elderly and patients where published contraindications are present. | 292-562 | 292 | 562 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and @SUBJECT$ @PREDICAT$ the elderly and @OBJECT$ where published contraindications are present. |
Fact | preserve | 482-484 | 482-484 | T36 | in | TREATS | 482 | 484 | preserve | 472-481 | 472-481 | T29 | metformin | OrganicChemical | 472 | 481 | preserve | 489-496 | 489-496 | T30 | elderly | AgeGroup | 489 | 496 | A15 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and metformin in the elderly and patients where published contraindications are present. | 292-562 | 292 | 562 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and @SUBJECT$ @PREDICAT$ the @OBJECT$ and patients where published contraindications are present. |
Fact | preserve | 653-657 | 653-657 | T47 | with | PROCESS_OF | 653 | 657 | preserve | 658-673 | 665-673 | T44 | type 2 diabetes | DiseaseOrSyndrome | 658 | 673 | preserve | 644-652 | 644-652 | T43 | patients | PatientOrDisabledGroup | 644 | 652 | A16 | METHODS: A retrospective review of the medical records for 150 consecutive patients with type 2 diabetes admitted to the hospital in mid-1997, was performed. | 563-732 | 563 | 732 | METHODS: A retrospective review of the medical records for 150 consecutive @OBJECT$ @PREDICAT$ @SUBJECT$ admitted to the hospital in mid-1997, was performed. |
Probable | preserve | 217-223 | 217-223 | T19 | induce | CAUSES | 217 | 223 | preserve | 192-205 | 192-205 | T14 | glibenclamide | OrganicChemical | 192 | 205 | preserve | 224-237 | 224-237 | T15 | hypoglycaemia | DiseaseOrSyndrome | 224 | 237 | A17 | The sulphonylureas, especially potent and long-acting agents such as glibenclamide, can induce hypoglycaemia, while metformin carries the risk of lactic acidosis. | 117-291 | 117 | 291 | The sulphonylureas, especially potent and long-acting agents such as @SUBJECT$ , can @PREDICAT$ @OBJECT$ , while metformin carries the risk of lactic acidosis. |
Fact | preserve | 311-321 | 311-321 | T34 | management | TREATS | 311 | 321 | preserve | 454-467 | 454-467 | T28 | glibenclamide | OrganicChemical | 454 | 467 | preserve | 325-340 | 332-340 | T22 | type 2 diabetes | DiseaseOrSyndrome | 325 | 340 | A18 | AIM: To review the management of type 2 diabetes at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of glibenclamide and metformin in the elderly and patients where published contraindications are present. | 292-562 | 292 | 562 | AIM: To review the @PREDICAT$ of @OBJECT$ at the major teaching hospital in Tasmania, Australia, principally to determine the extent of use of @SUBJECT$ and metformin in the elderly and patients where published contraindications are present. |
Fact | preserve | 2189-2191 | 2189-2191 | T131 | in | TREATS | 2,189 | 2,191 | preserve | 2161-2170 | 2161-2170 | T123 | metformin | OrganicChemical | 2,161 | 2,170 | preserve | 2208-2216 | 2208-2216 | T126 | patients | PatientOrDisabledGroup | 2,208 | 2,216 | A19 | CONCLUSIONS: There was evidence of over-utilization of metformin and glibenclamide in type 2 diabetes patients most at risk of adverse reactions. | 2100-2257 | 2,100 | 2,257 | CONCLUSIONS: There was evidence of over-utilization of @SUBJECT$ and glibenclamide @PREDICAT$ type 2 diabetes @OBJECT$ most at risk of adverse reactions. |
Fact | preserve | 2189-2191 | 2189-2191 | T131 | in | TREATS | 2,189 | 2,191 | preserve | 2175-2188 | 2175-2188 | T124 | glibenclamide | OrganicChemical | 2,175 | 2,188 | preserve | 2192-2207 | 2199-2207 | T125 | type 2 diabetes | DiseaseOrSyndrome | 2,192 | 2,207 | A20 | CONCLUSIONS: There was evidence of over-utilization of metformin and glibenclamide in type 2 diabetes patients most at risk of adverse reactions. | 2100-2257 | 2,100 | 2,257 | CONCLUSIONS: There was evidence of over-utilization of metformin and @SUBJECT$ @PREDICAT$ @OBJECT$ patients most at risk of adverse reactions. |
Fact | preserve | 1770-1775 | 1770-1775 | T116 | using | ADMINISTERED_TO | 1,770 | 1,775 | preserve | 1776-1785 | 1776-1785 | T104 | metformin | OrganicChemical | 1,776 | 1,785 | preserve | 1755-1763 | 1755-1763 | T103 | patients | PatientOrDisabledGroup | 1,755 | 1,763 | A21 | Sixty-six out of 70 patients (94%) using metformin had at least one contraindication according to the manufacturer's prescribing information, 57% of patients had two or three contraindications and 14% of patients had more than three contraindications. | 1735-2006 | 1,735 | 2,006 | Sixty-six out of 70 @OBJECT$ (94%) @PREDICAT$ @SUBJECT$ had at least one contraindication according to the manufacturer's prescribing information, 57% of patients had two or three contraindications and 14% of patients had more than three contraindications. |
Fact | preserve | 1871-1873 | 1871-1873 | T102 | in | PROCESS_OF | 1,871 | 1,873 | preserve | 1847-1860 | 1854-1860 | T97 | breast cancer | NeoplasticProcess | 1,847 | 1,860 | preserve | 1889-1894 | 1889-1894 | T99 | women | PopulationGroup | 1,889 | 1,894 | A2 | All evidence supports a causal relation between both endogenous estrogens and the use of postmenopausal estrogens and progestins and breast cancer incidence in postmenopausal women. | 1702-1895 | 1,702 | 1,895 | All evidence supports a causal relation between both endogenous estrogens and the use of postmenopausal estrogens and progestins and @SUBJECT$ incidence @PREDICAT$ postmenopausal @OBJECT$ . |
Fact | preserve | 734-736 | 734-736 | T35 | in | PROCESS_OF | 734 | 736 | preserve | 708-714 | 708-714 | T33 | cancer | NeoplasticProcess | 708 | 714 | preserve | 740-750 | 740-750 | T34 | individual | Human | 740 | 750 | A4 | A cause of cancer is defined as a factor that increases the probability that cancer will develop in an individual. | 625-751 | 625 | 751 | A cause of cancer is defined as a factor that increases the probability that @SUBJECT$ will develop @PREDICAT$ an @OBJECT$ . |
Fact | preserve | 656-658 | 656-658 | T60 | on | LOCATION_OF | 656 | 658 | preserve | 686-695 | 686-695 | T59 | membranes | Tissue | 686 | 695 | preserve | 627-634 | 627-634 | T55 | protein | AminoAcidPeptideOrProtein | 627 | 634 | A1 | Spot synthesis combined with peptide library techniques is a useful tool for studying protein-peptide interactions on continuous cellulose membranes. | 535-696 | 535 | 696 | Spot synthesis combined with peptide library techniques is a useful tool for studying @OBJECT$ -peptide interactions @PREDICAT$ continuous cellulose @SUBJECT$ . |
Fact | preserve | 1064-1071 | 1064-1071 | T97 | treated | TREATS | 1,064 | 1,071 | preserve | 1077-1079 | 1077-1079 | T91 | SK | AminoAcidPeptideOrProtein | 1,077 | 1,079 | preserve | 1055-1063 | 1055-1063 | T90 | patients | PatientOrDisabledGroup | 1,055 | 1,063 | A2 | However, patients treated with SK tend, in general, to show a common regional binding pattern, including residues 1-20, 130-149, 170-189, and 390-399. | 1046-1208 | 1,046 | 1,208 | However, @OBJECT$ @PREDICAT$ with @SUBJECT$ tend, in general, to show a common regional binding pattern, including residues 1-20, 130-149, 170-189, and 390-399. |
Fact | preserve | 455-465 | 458-465 | T47 | SK therapy | USES | 455 | 465 | preserve | 458-465 | 458-465 | T41 | therapy | TherapeuticOrPreventiveProcedure | 458 | 465 | preserve | 455-457 | 455-457 | T40 | SK | AminoAcidPeptideOrProtein | 455 | 457 | A3 | High Ab titers might provoke severe immune reactions during SK therapy and neutralize SK activity, preventing effective thrombolysis. | 389-534 | 389 | 534 | High Ab titers might provoke severe immune reactions during @OBJECT$ @PREDICAT$ @SUBJECT$ and neutralize SK activity, preventing effective thrombolysis. |
Fact | preserve | 823-827 | 823-827 | T73 | from | LOCATION_OF | 823 | 827 | preserve | 828-836 | 828-836 | T69 | patients | PatientOrDisabledGroup | 828 | 836 | preserve | 786-801 | 794-801 | T65 | peptide library | AminoAcidPeptideOrProtein | 786 | 801 | A6 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. | 697-864 | 697 | 864 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized @OBJECT$ and human total sera @PREDICAT$ @SUBJECT$ receiving SK therapy. |
Fact | preserve | 291-301 | 294-301 | T31 | SK therapy | ISA | 291 | 301 | preserve | 291-293 | 291-293 | T23 | SK | AminoAcidPeptideOrProtein | 291 | 293 | preserve | 294-301 | 294-301 | T24 | therapy | TherapeuticOrPreventiveProcedure | 294 | 301 | A7 | Therefore, resulting from SK therapy, patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. | 265-388 | 265 | 388 | Therefore, resulting from @SUBJECT$ @PREDICAT$ @OBJECT$ , patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. |
Fact | preserve | 66-93 | 86-93 | T9 | streptokinase therapy | USES | 66 | 93 | preserve | 66-79 | 66-79 | T5 | streptokinase | AminoAcidPeptideOrProtein | 66 | 79 | preserve | 66-79 | 66-79 | T5 | streptokinase | AminoAcidPeptideOrProtein | 66 | 79 | A8 | Mapping of the antigenic regions of streptokinase in humans after streptokinase therapy. | 0-94 | 0 | 94 | Mapping of the antigenic regions of streptokinase in humans after @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 843-852 | 843-852 | T74 | receiving | ADMINISTERED_TO | 843 | 852 | preserve | 856-863 | 856-863 | T71 | therapy | TherapeuticOrPreventiveProcedure | 856 | 863 | preserve | 828-836 | 828-836 | T69 | patients | PatientOrDisabledGroup | 828 | 836 | A10 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. | 697-864 | 697 | 864 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from @OBJECT$ @PREDICAT$ SK @SUBJECT$ . |
Fact | preserve | 95-158 | 131-135 | T17 | Streptokinase (SK) is efficaciously used as a thrombolytic drug | TREATS | 95 | 158 | preserve | 95-108 | 95-108 | T11 | Streptokinase | AminoAcidPeptideOrProtein | 95 | 108 | preserve | 186-207 | 197-207 | T14 | myocardial infarction | DiseaseOrSyndrome | 186 | 207 | A11 | Streptokinase (SK) is efficaciously used as a thrombolytic drug for the treatment of myocardial infarction. | 95-208 | 95 | 208 | @SUBJECT$ @PREDICAT$ for the treatment of @OBJECT$ . |
Fact | preserve | 167-176 | 167-176 | T16 | treatment | TREATS | 167 | 176 | preserve | 141-158 | 154-158 | T12 | thrombolytic drug | PharmacologicSubstance | 141 | 158 | preserve | 186-207 | 197-207 | T14 | myocardial infarction | DiseaseOrSyndrome | 186 | 207 | A12 | Streptokinase (SK) is efficaciously used as a thrombolytic drug for the treatment of myocardial infarction. | 95-208 | 95 | 208 | Streptokinase (SK) is efficaciously used as a @SUBJECT$ for the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 853-863 | 856-863 | T76 | SK therapy | ADMINISTERED_TO | 853 | 863 | preserve | 853-855 | 853-855 | T70 | SK | AminoAcidPeptideOrProtein | 853 | 855 | preserve | 828-836 | 828-836 | T69 | patients | PatientOrDisabledGroup | 828 | 836 | A14 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. | 697-864 | 697 | 864 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from @OBJECT$ receiving @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 455-465 | 458-465 | T46 | SK therapy | ISA | 455 | 465 | preserve | 455-457 | 455-457 | T40 | SK | AminoAcidPeptideOrProtein | 455 | 457 | preserve | 458-465 | 458-465 | T41 | therapy | TherapeuticOrPreventiveProcedure | 458 | 465 | A15 | High Ab titers might provoke severe immune reactions during SK therapy and neutralize SK activity, preventing effective thrombolysis. | 389-534 | 389 | 534 | High Ab titers might provoke severe immune reactions during @SUBJECT$ @PREDICAT$ @OBJECT$ and neutralize SK activity, preventing effective thrombolysis. |
Fact | preserve | 66-93 | 86-93 | T7 | streptokinase therapy | ISA | 66 | 93 | preserve | 66-79 | 66-79 | T5 | streptokinase | AminoAcidPeptideOrProtein | 66 | 79 | preserve | 86-93 | 86-93 | T6 | therapy | TherapeuticOrPreventiveProcedure | 86 | 93 | A17 | Mapping of the antigenic regions of streptokinase in humans after streptokinase therapy. | 0-94 | 0 | 94 | Mapping of the antigenic regions of streptokinase in humans after @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 291-301 | 294-301 | T32 | SK therapy | USES | 291 | 301 | preserve | 294-301 | 294-301 | T24 | therapy | TherapeuticOrPreventiveProcedure | 294 | 301 | preserve | 291-293 | 291-293 | T23 | SK | AminoAcidPeptideOrProtein | 291 | 293 | A19 | Therefore, resulting from SK therapy, patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. | 265-388 | 265 | 388 | Therefore, resulting from @OBJECT$ @PREDICAT$ @SUBJECT$ , patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. |
Fact | preserve | 95-158 | 131-135 | T15 | Streptokinase (SK) is efficaciously used as a thrombolytic drug | ISA | 95 | 158 | preserve | 95-108 | 95-108 | T11 | Streptokinase | AminoAcidPeptideOrProtein | 95 | 108 | preserve | 141-158 | 154-158 | T12 | thrombolytic drug | PharmacologicSubstance | 141 | 158 | A20 | Streptokinase (SK) is efficaciously used as a thrombolytic drug for the treatment of myocardial infarction. | 95-208 | 95 | 208 | @SUBJECT$ @PREDICAT$ @OBJECT$ for the treatment of myocardial infarction. |
Fact | preserve | 853-863 | 856-863 | T75 | SK therapy | USES | 853 | 863 | preserve | 856-863 | 856-863 | T71 | therapy | TherapeuticOrPreventiveProcedure | 856 | 863 | preserve | 853-855 | 853-855 | T70 | SK | AminoAcidPeptideOrProtein | 853 | 855 | A21 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. | 697-864 | 697 | 864 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 853-863 | 856-863 | T72 | SK therapy | ISA | 853 | 863 | preserve | 853-855 | 853-855 | T70 | SK | AminoAcidPeptideOrProtein | 853 | 855 | preserve | 856-863 | 856-863 | T71 | therapy | TherapeuticOrPreventiveProcedure | 856 | 863 | A22 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. | 697-864 | 697 | 864 | Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 18-20 | 18-20 | T3 | in | TREATS | 18 | 20 | preserve | 0-17 | 7-17 | T1 | Asthma management | HealthCareActivity | 0 | 17 | preserve | 21-27 | 21-27 | T2 | adults | AgeGroup | 21 | 27 | A4 | Asthma management in adults. | 0-28 | 0 | 28 | @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 606-624 | 616-624 | T48 | asthmatic patients | PROCESS_OF | 606 | 624 | preserve | 606-615 | 606-615 | T32 | asthmatic | DiseaseOrSyndrome | 606 | 615 | preserve | 616-624 | 616-624 | T33 | patients | PatientOrDisabledGroup | 616 | 624 | A5 | DISCUSSION: Morbidity due to asthma and quality of life for asthmatic patients can be improved by: identifying preventable causes of persistent asthma symptoms; reviewing inhaler technique; targeting high risk for more intensive monitoring; familiarity with the drugs used to treat asthma. | 540-853 | 540 | 853 | DISCUSSION: Morbidity due to asthma and quality of life for @SUBJECT$ @PREDICAT$ @OBJECT$ can be improved by: identifying preventable causes of persistent asthma symptoms; reviewing inhaler technique; targeting high risk for more intensive monitoring; familiarity with the drugs used to treat asthma. |
Fact | preserve | 840-845 | 840-845 | T50 | treat | TREATS | 840 | 845 | preserve | 826-831 | 826-831 | T45 | drugs | PharmacologicSubstance | 826 | 831 | preserve | 846-852 | 846-852 | T46 | asthma | DiseaseOrSyndrome | 846 | 852 | A6 | DISCUSSION: Morbidity due to asthma and quality of life for asthmatic patients can be improved by: identifying preventable causes of persistent asthma symptoms; reviewing inhaler technique; targeting high risk for more intensive monitoring; familiarity with the drugs used to treat asthma. | 540-853 | 540 | 853 | DISCUSSION: Morbidity due to asthma and quality of life for asthmatic patients can be improved by: identifying preventable causes of persistent asthma symptoms; reviewing inhaler technique; targeting high risk for more intensive monitoring; familiarity with the @SUBJECT$ used to @PREDICAT$ @OBJECT$ . |
Fact | preserve | 586-588 | 586-588 | T47 | in | TREATS | 586 | 588 | preserve | 572-585 | 572-585 | T30 | esophagectomy | TherapeuticOrPreventiveProcedure | 572 | 585 | preserve | 603-623 | 614-623 | T32 | high-grade dysplasia | NeoplasticProcess | 603 | 623 | A1 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of @SUBJECT$ @PREDICAT$ patients with @OBJECT$ ; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 1393-1397 | 1393-1397 | T82 | with | PROCESS_OF | 1,393 | 1,397 | preserve | 1398-1402 | 1398-1402 | T81 | GERD | DiseaseOrSyndrome | 1,398 | 1,402 | preserve | 1378-1386 | 1378-1386 | T80 | patients | PatientOrDisabledGroup | 1,378 | 1,386 | A2 | Barrett's metaplasia was present in 72 (13%) of the 535 patients with GERD. | 1322-1403 | 1,322 | 1,403 | Barrett's metaplasia was present in 72 (13%) of the 535 @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 586-588 | 586-588 | T47 | in | TREATS | 586 | 588 | preserve | 572-585 | 572-585 | T30 | esophagectomy | TherapeuticOrPreventiveProcedure | 572 | 585 | preserve | 589-597 | 589-597 | T31 | patients | PatientOrDisabledGroup | 589 | 597 | A3 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of @SUBJECT$ @PREDICAT$ @OBJECT$ with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 1277-1286 | 1277-1286 | T77 | underwent | TREATS | 1,277 | 1,286 | preserve | 1305-1320 | 1305-1320 | T75 | esophagectomies | TherapeuticOrPreventiveProcedure | 1,305 | 1,320 | preserve | 1256-1276 | 1267-1276 | T74 | high-grade dysplasia | NeoplasticProcess | 1,256 | 1,276 | A4 | Eleven other consecutive patients with high-grade dysplasia underwent transhiatal esophagectomies. | 1211-1321 | 1,211 | 1,321 | Eleven other consecutive patients with @OBJECT$ @PREDICAT$ transhiatal @SUBJECT$ . |
Fact | preserve | 424-428 | 424-428 | T42 | with | PROCESS_OF | 424 | 428 | preserve | 429-433 | 429-433 | T23 | GERD | DiseaseOrSyndrome | 429 | 433 | preserve | 415-423 | 415-423 | T22 | patients | PatientOrDisabledGroup | 415 | 423 | A5 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among @OBJECT$ @PREDICAT$ @SUBJECT$ ; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 1980-1982 | 1980-1982 | T115 | in | PROCESS_OF | 1,980 | 1,982 | preserve | 1953-1979 | 1970-1979 | T108 | high-grade dysplasia | NeoplasticProcess | 1,953 | 1,979 | preserve | 1989-1997 | 1989-1997 | T110 | patients | PatientOrDisabledGroup | 1,989 | 1,997 | A6 | The specimens showed high-grade dysplasia in seven patients and invasive adenocarcinoma (undiagnosed preoperatively) in four (36%). | 1932-2075 | 1,932 | 2,075 | The specimens showed @SUBJECT$ @PREDICAT$ seven @OBJECT$ and invasive adenocarcinoma (undiagnosed preoperatively) in four (36%). |
Uncommitted | preserve | 491-498 | 491-498 | T43 | control | TREATS | 491 | 498 | preserve | 454-487 | 473-487 | T25 | laparoscopic fundoplication | TherapeuticOrPreventiveProcedure | 454 | 487 | preserve | 499-507 | 499-507 | T26 | symptoms | SignOrSymptom | 499 | 507 | A7 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of @SUBJECT$ to @PREDICAT$ @OBJECT$ in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 1131-1135 | 1131-1135 | T70 | with | PROCESS_OF | 1,131 | 1,135 | preserve | 1136-1140 | 1136-1140 | T67 | GERD | DiseaseOrSyndrome | 1,136 | 1,140 | preserve | 1122-1130 | 1122-1130 | T66 | patients | PatientOrDisabledGroup | 1,122 | 1,130 | A8 | Thirty-eight symptomatic patients with GERD and Barrett's metaplasia underwent laparoscopic fundoplication. | 1097-1210 | 1,097 | 1,210 | Thirty-eight symptomatic @OBJECT$ @PREDICAT$ @SUBJECT$ and Barrett's metaplasia underwent laparoscopic fundoplication. |
Fact | preserve | 520-524 | 520-524 | T45 | with | PROCESS_OF | 520 | 524 | preserve | 535-545 | 535-545 | T28 | metaplasia | CellOrMolecularDysfunction | 535 | 545 | preserve | 511-519 | 511-519 | T27 | patients | PatientOrDisabledGroup | 511 | 519 | A10 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in @OBJECT$ @PREDICAT$ Barrett's @SUBJECT$ ; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 1172-1181 | 1172-1181 | T71 | underwent | TREATS | 1,172 | 1,181 | preserve | 1182-1209 | 1195-1209 | T69 | laparoscopic fundoplication | TherapeuticOrPreventiveProcedure | 1,182 | 1,209 | preserve | 1161-1171 | 1161-1171 | T68 | metaplasia | CellOrMolecularDysfunction | 1,161 | 1,171 | A11 | Thirty-eight symptomatic patients with GERD and Barrett's metaplasia underwent laparoscopic fundoplication. | 1097-1210 | 1,097 | 1,210 | Thirty-eight symptomatic patients with GERD and Barrett's @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 368-377 | 368-377 | T41 | incidence | OCCURS_IN | 368 | 377 | preserve | 398-408 | 398-408 | T21 | metaplasia | CellOrMolecularDysfunction | 398 | 408 | preserve | 415-423 | 415-423 | T22 | patients | PatientOrDisabledGroup | 415 | 423 | A12 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the @PREDICAT$ of Barrett's @SUBJECT$ among @OBJECT$ with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 774-818 | 808-818 | T40 | geographic region (northern California | ISA | 774 | 818 | preserve | 808-818 | 808-818 | T39 | California | GeographicArea | 808 | 818 | preserve | 774-791 | 785-791 | T38 | geographic region | GeographicArea | 774 | 791 | A13 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large @OBJECT$ @PREDICAT$ @SUBJECT$ ). |
Fact | preserve | 2348-2352 | 2348-2352 | T150 | with | PROCESS_OF | 2,348 | 2,352 | preserve | 2363-2373 | 2363-2373 | T128 | metaplasia | CellOrMolecularDysfunction | 2,363 | 2,373 | preserve | 2339-2347 | 2339-2347 | T127 | patients | PatientOrDisabledGroup | 2,339 | 2,347 | A14 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. | 2076-2825 | 2,076 | 2,825 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in @OBJECT$ @PREDICAT$ Barrett's @SUBJECT$ ; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. |
Fact | preserve | 1456-1465 | 1456-1465 | T93 | underwent | TREATS | 1,456 | 1,465 | preserve | 1472-1499 | 1485-1499 | T86 | laparoscopic fundoplication | TherapeuticOrPreventiveProcedure | 1,472 | 1,499 | preserve | 1443-1451 | 1443-1451 | T85 | patients | PatientOrDisabledGroup | 1,443 | 1,451 | A16 | The following results were achieved in patients who underwent laparoscopic fundoplication (n = 38): Heartburn resolved in 95% of patients, regurgitation in 93% of patients, and cough in 100% of patients. | 1404-1619 | 1,404 | 1,619 | The following results were achieved in @OBJECT$ who @PREDICAT$ @SUBJECT$ (n = 38): Heartburn resolved in 95% of patients, regurgitation in 93% of patients, and cough in 100% of patients. |
Fact | preserve | 1251-1255 | 1251-1255 | T76 | with | PROCESS_OF | 1,251 | 1,255 | preserve | 1256-1276 | 1267-1276 | T74 | high-grade dysplasia | NeoplasticProcess | 1,256 | 1,276 | preserve | 1242-1250 | 1242-1250 | T73 | patients | PatientOrDisabledGroup | 1,242 | 1,250 | A17 | Eleven other consecutive patients with high-grade dysplasia underwent transhiatal esophagectomies. | 1211-1321 | 1,211 | 1,321 | Eleven other consecutive @OBJECT$ @PREDICAT$ @SUBJECT$ underwent transhiatal esophagectomies. |
Probable | preserve | 74-76 | 74-76 | T10 | in | PROCESS_OF | 74 | 76 | preserve | 51-61 | 51-61 | T4 | metaplasia | CellOrMolecularDysfunction | 51 | 61 | preserve | 77-85 | 77-85 | T5 | patients | PatientOrDisabledGroup | 77 | 85 | A19 | Barrett's metaplasia can develop in patients with gastroesophageal reflux disease (GERD), and metaplasia can evolve into dysplasia and adenocarcinoma. | 41-197 | 41 | 197 | Barrett's @SUBJECT$ can develop @PREDICAT$ @OBJECT$ with gastroesophageal reflux disease (GERD), and metaplasia can evolve into dysplasia and adenocarcinoma. |
Fact | preserve | 598-602 | 598-602 | T48 | with | PROCESS_OF | 598 | 602 | preserve | 603-623 | 614-623 | T32 | high-grade dysplasia | NeoplasticProcess | 603 | 623 | preserve | 589-597 | 589-597 | T31 | patients | PatientOrDisabledGroup | 589 | 597 | A20 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in @OBJECT$ @PREDICAT$ @SUBJECT$ ; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 2336-2338 | 2336-2338 | T149 | in | PROCESS_OF | 2,336 | 2,338 | preserve | 2331-2335 | 2331-2335 | T126 | GERD | DiseaseOrSyndrome | 2,331 | 2,335 | preserve | 2339-2347 | 2339-2347 | T127 | patients | PatientOrDisabledGroup | 2,339 | 2,347 | A21 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. | 2076-2825 | 2,076 | 2,825 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of @SUBJECT$ @PREDICAT$ @OBJECT$ with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. |
Fact | preserve | 86-90 | 86-90 | T12 | with | PROCESS_OF | 86 | 90 | preserve | 91-122 | 115-122 | T6 | gastroesophageal reflux disease | DiseaseOrSyndrome | 91 | 122 | preserve | 77-85 | 77-85 | T5 | patients | PatientOrDisabledGroup | 77 | 85 | A22 | Barrett's metaplasia can develop in patients with gastroesophageal reflux disease (GERD), and metaplasia can evolve into dysplasia and adenocarcinoma. | 41-197 | 41 | 197 | Barrett's metaplasia can develop in @OBJECT$ @PREDICAT$ @SUBJECT$ (GERD), and metaplasia can evolve into dysplasia and adenocarcinoma. |
Fact | preserve | 2182-2186 | 2182-2186 | T147 | with | PROCESS_OF | 2,182 | 2,186 | preserve | 2187-2191 | 2187-2191 | T120 | GERD | DiseaseOrSyndrome | 2,187 | 2,191 | preserve | 2173-2181 | 2173-2181 | T119 | patients | PatientOrDisabledGroup | 2,173 | 2,181 | A23 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. | 2076-2825 | 2,076 | 2,825 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of @OBJECT$ @PREDICAT$ @SUBJECT$ being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. |
Fact | preserve | 2304-2306 | 2304-2306 | T148 | in | TREATS | 2,304 | 2,306 | preserve | 2248-2275 | 2261-2275 | T123 | laparoscopic fundoplication | TherapeuticOrPreventiveProcedure | 2,248 | 2,275 | preserve | 2319-2327 | 2319-2327 | T125 | symptoms | SignOrSymptom | 2,319 | 2,327 | A24 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. | 2076-2825 | 2,076 | 2,825 | These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) @SUBJECT$ was highly successful @PREDICAT$ controlling @OBJECT$ of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area. |
Fact | preserve | 508-510 | 508-510 | T44 | in | PROCESS_OF | 508 | 510 | preserve | 499-507 | 499-507 | T26 | symptoms | SignOrSymptom | 499 | 507 | preserve | 511-519 | 511-519 | T27 | patients | PatientOrDisabledGroup | 511 | 519 | A25 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). | 290-820 | 290 | 820 | The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control @SUBJECT$ @PREDICAT$ @OBJECT$ with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). |
Fact | preserve | 1172-1181 | 1172-1181 | T71 | underwent | TREATS | 1,172 | 1,181 | preserve | 1182-1209 | 1195-1209 | T69 | laparoscopic fundoplication | TherapeuticOrPreventiveProcedure | 1,182 | 1,209 | preserve | 1136-1140 | 1136-1140 | T67 | GERD | DiseaseOrSyndrome | 1,136 | 1,140 | A27 | Thirty-eight symptomatic patients with GERD and Barrett's metaplasia underwent laparoscopic fundoplication. | 1097-1210 | 1,097 | 1,210 | Thirty-eight symptomatic patients with @OBJECT$ and Barrett's metaplasia @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 986-995 | 986-995 | T63 | diagnosis | DIAGNOSES | 986 | 995 | preserve | 1050-1059 | 1050-1059 | T61 | endoscopy | DiagnosticProcedure | 1,050 | 1,059 | preserve | 999-1003 | 999-1003 | T58 | GERD | DiseaseOrSyndrome | 999 | 1,003 | A28 | Five-hundred thirty-five patients evaluated between October 1989 and February 1997 at the University of California San Francisco Swallowing Center had a diagnosis of GERD established by upper gastrointestinal series, endoscopy, manometry, and pH monitoring. | 821-1096 | 821 | 1,096 | Five-hundred thirty-five patients evaluated between October 1989 and February 1997 at the University of California San Francisco Swallowing Center had a @PREDICAT$ of @OBJECT$ established by upper gastrointestinal series, @SUBJECT$ , manometry, and pH monitoring. |
Fact | preserve | 898-943 | 906-910 | T68 | enzymes such as angiotensin converting enzyme | ISA | 898 | 943 | preserve | 914-943 | 937-943 | T63 | angiotensin converting enzyme | AminoAcidPeptideOrProtein | 914 | 943 | preserve | 898-905 | 898-905 | T62 | enzymes | Enzyme | 898 | 905 | A1 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @OBJECT$ @PREDICAT$ @SUBJECT$ , carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. |
Fact | preserve | 898-943 | 906-910 | T75 | enzymes such as angiotensin converting enzyme | LOCATION_OF | 898 | 943 | preserve | 1046-1053 | 1046-1053 | T67 | tissues | Tissue | 1,046 | 1,053 | preserve | 914-943 | 937-943 | T63 | angiotensin converting enzyme | AminoAcidPeptideOrProtein | 914 | 943 | A2 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @PREDICAT$ @OBJECT$ , carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in @SUBJECT$ . |
Fact | preserve | 488-495 | 488-495 | T41 | induced | CAUSES | 488 | 495 | preserve | 499-512 | 499-512 | T30 | Dexamethasone | PharmacologicSubstance | 499 | 512 | preserve | 475-487 | 475-487 | T29 | hypertension | DiseaseOrSyndrome | 475 | 487 | A3 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). | 137-519 | 137 | 519 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of @OBJECT$ @PREDICAT$ by @SUBJECT$ (Dex). |
Fact | preserve | 1043-1045 | 1043-1045 | T74 | in | LOCATION_OF | 1,043 | 1,045 | preserve | 1046-1053 | 1046-1053 | T67 | tissues | Tissue | 1,046 | 1,053 | preserve | 898-905 | 898-905 | T62 | enzymes | Enzyme | 898 | 905 | A4 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @OBJECT$ such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 898-943 | 906-910 | T75 | enzymes such as angiotensin converting enzyme | LOCATION_OF | 898 | 943 | preserve | 1046-1053 | 1046-1053 | T67 | tissues | Tissue | 1,046 | 1,053 | preserve | 945-963 | 945-963 | T64 | carboxypeptidase-N | AminoAcidPeptideOrProtein | 945 | 963 | A6 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @PREDICAT$ , @OBJECT$ and leucine aminopeptidase were found to be elevated in serum as well as in @SUBJECT$ . |
Fact | preserve | 898-943 | 906-910 | T68 | enzymes such as angiotensin converting enzyme | ISA | 898 | 943 | preserve | 945-963 | 945-963 | T64 | carboxypeptidase-N | AminoAcidPeptideOrProtein | 945 | 963 | preserve | 898-905 | 898-905 | T62 | enzymes | Enzyme | 898 | 905 | A8 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @OBJECT$ @PREDICAT$ , @SUBJECT$ and leucine aminopeptidase were found to be elevated in serum as well as in tissues. |
Fact | preserve | 223-270 | 233-237 | T31 | proteases such as angiotensin converting enzyme | ISA | 223 | 270 | preserve | 327-334 | 327-334 | T20 | plasmin | AminoAcidPeptideOrProtein | 327 | 334 | preserve | 223-232 | 223-232 | T15 | proteases | AminoAcidPeptideOrProtein | 223 | 232 | A10 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). | 137-519 | 137 | 519 | This study was designed to investigate the alterations in the levels of various @OBJECT$ @PREDICAT$ (ACE), kallikrein, aminopeptidases, urokinase and @SUBJECT$ in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). |
Fact | preserve | 1023-1025 | 1023-1025 | T71 | in | LOCATION_OF | 1,023 | 1,025 | preserve | 1026-1031 | 1026-1031 | T66 | serum | BodySubstance | 1,026 | 1,031 | preserve | 968-996 | 982-996 | T65 | leucine aminopeptidase | AminoAcidPeptideOrProtein | 968 | 996 | A12 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and @OBJECT$ were found to be elevated @PREDICAT$ @SUBJECT$ as well as in tissues. |
Fact | preserve | 223-270 | 233-237 | T31 | proteases such as angiotensin converting enzyme | ISA | 223 | 270 | preserve | 278-288 | 278-288 | T17 | kallikrein | AminoAcidPeptideOrProtein | 278 | 288 | preserve | 223-232 | 223-232 | T15 | proteases | AminoAcidPeptideOrProtein | 223 | 232 | A13 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). | 137-519 | 137 | 519 | This study was designed to investigate the alterations in the levels of various @OBJECT$ @PREDICAT$ (ACE), @SUBJECT$ , aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). |
Fact | preserve | 223-270 | 233-237 | T31 | proteases such as angiotensin converting enzyme | ISA | 223 | 270 | preserve | 296-311 | 296-311 | T18 | aminopeptidases | AminoAcidPeptideOrProtein | 296 | 311 | preserve | 223-232 | 223-232 | T15 | proteases | AminoAcidPeptideOrProtein | 223 | 232 | A14 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). | 137-519 | 137 | 519 | This study was designed to investigate the alterations in the levels of various @OBJECT$ @PREDICAT$ (ACE), kallikrein, @SUBJECT$ , urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). |
Fact | preserve | 1234-1241 | 1234-1241 | T98 | altered | INTERACTS_WITH | 1,234 | 1,241 | preserve | 1224-1227 | 1224-1227 | T89 | Dex | PharmacologicSubstance | 1,224 | 1,227 | preserve | 1262-1271 | 1262-1271 | T91 | proteases | AminoAcidPeptideOrProtein | 1,262 | 1,271 | A15 | Thus, treatment with Dex altered the levels of these proteases which might have a role in the pathogenesis of hypertension and in altered blood coagulation. | 1203-1371 | 1,203 | 1,371 | Thus, treatment with @SUBJECT$ @PREDICAT$ the levels of these @OBJECT$ which might have a role in the pathogenesis of hypertension and in altered blood coagulation. |
Fact | preserve | 61-69 | 61-69 | T10 | involved | AFFECTS | 61 | 69 | preserve | 51-60 | 51-60 | T5 | proteases | AminoAcidPeptideOrProtein | 51 | 60 | preserve | 110-127 | 116-127 | T8 | blood coagulation | OrganOrTissueFunction | 110 | 127 | A16 | Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats. | 0-136 | 0 | 136 | Dexamethasone induced alterations in the levels of @SUBJECT$ @PREDICAT$ in blood pressure homeostasis and @OBJECT$ in rats. |
Fact | preserve | 898-943 | 906-910 | T75 | enzymes such as angiotensin converting enzyme | LOCATION_OF | 898 | 943 | preserve | 1046-1053 | 1046-1053 | T67 | tissues | Tissue | 1,046 | 1,053 | preserve | 968-996 | 982-996 | T65 | leucine aminopeptidase | AminoAcidPeptideOrProtein | 968 | 996 | A18 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @PREDICAT$ , carboxypeptidase-N and @OBJECT$ were found to be elevated in serum as well as in @SUBJECT$ . |
Fact | preserve | 1023-1025 | 1023-1025 | T71 | in | LOCATION_OF | 1,023 | 1,025 | preserve | 1026-1031 | 1026-1031 | T66 | serum | BodySubstance | 1,026 | 1,031 | preserve | 914-943 | 937-943 | T63 | angiotensin converting enzyme | AminoAcidPeptideOrProtein | 914 | 943 | A19 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of enzymes such as @OBJECT$ , carboxypeptidase-N and leucine aminopeptidase were found to be elevated @PREDICAT$ @SUBJECT$ as well as in tissues. |
Fact | preserve | 61-69 | 61-69 | T10 | involved | AFFECTS | 61 | 69 | preserve | 51-60 | 51-60 | T5 | proteases | AminoAcidPeptideOrProtein | 51 | 60 | preserve | 94-105 | 94-105 | T7 | homeostasis | OrganismFunction | 94 | 105 | A21 | Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats. | 0-136 | 0 | 136 | Dexamethasone induced alterations in the levels of @SUBJECT$ @PREDICAT$ in blood pressure @OBJECT$ and blood coagulation in rats. |
Fact | preserve | 528-540 | 528-540 | T50 | administered | ADMINISTERED_TO | 528 | 540 | preserve | 520-523 | 520-523 | T42 | Dex | PharmacologicSubstance | 520 | 523 | preserve | 555-566 | 562-566 | T43 | Wistar rats | Mammal | 555 | 566 | A22 | Dex was administered to Male Wistar rats (180-200 g body weight) at a dosage of 2.5 mg/kg/week subcutaneously on alternate days for 2 weeks. | 520-673 | 520 | 673 | @SUBJECT$ was @PREDICAT$ to Male @OBJECT$ (180-200 g body weight) at a dosage of 2.5 mg/kg/week subcutaneously on alternate days for 2 weeks. |
Fact | preserve | 1219-1223 | 1219-1223 | T97 | with | USES | 1,219 | 1,223 | preserve | 1209-1218 | 1209-1218 | T88 | treatment | TherapeuticOrPreventiveProcedure | 1,209 | 1,218 | preserve | 1224-1227 | 1224-1227 | T89 | Dex | PharmacologicSubstance | 1,224 | 1,227 | A23 | Thus, treatment with Dex altered the levels of these proteases which might have a role in the pathogenesis of hypertension and in altered blood coagulation. | 1203-1371 | 1,203 | 1,371 | Thus, @SUBJECT$ @PREDICAT$ @OBJECT$ altered the levels of these proteases which might have a role in the pathogenesis of hypertension and in altered blood coagulation. |
Fact | preserve | 223-270 | 233-237 | T31 | proteases such as angiotensin converting enzyme | ISA | 223 | 270 | preserve | 241-270 | 264-270 | T16 | angiotensin converting enzyme | AminoAcidPeptideOrProtein | 241 | 270 | preserve | 223-232 | 223-232 | T15 | proteases | AminoAcidPeptideOrProtein | 223 | 232 | A24 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). | 137-519 | 137 | 519 | This study was designed to investigate the alterations in the levels of various @OBJECT$ @PREDICAT$ @SUBJECT$ (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). |
Fact | preserve | 1110-1112 | 1110-1112 | T86 | in | LOCATION_OF | 1,110 | 1,112 | preserve | 1113-1118 | 1113-1118 | T79 | serum | BodySubstance | 1,113 | 1,118 | preserve | 1074-1084 | 1074-1084 | T78 | kallikrein | AminoAcidPeptideOrProtein | 1,074 | 1,084 | A25 | The level of kallikrein was observed to decrease in serum and tissues and that of thrombin, plasmin and urokinase exhibited variations. | 1055-1202 | 1,055 | 1,202 | The level of @OBJECT$ was observed to decrease @PREDICAT$ @SUBJECT$ and tissues and that of thrombin, plasmin and urokinase exhibited variations. |
Fact | preserve | 1110-1112 | 1110-1112 | T86 | in | LOCATION_OF | 1,110 | 1,112 | preserve | 1123-1130 | 1123-1130 | T80 | tissues | Tissue | 1,123 | 1,130 | preserve | 1074-1084 | 1074-1084 | T78 | kallikrein | AminoAcidPeptideOrProtein | 1,074 | 1,084 | A26 | The level of kallikrein was observed to decrease in serum and tissues and that of thrombin, plasmin and urokinase exhibited variations. | 1055-1202 | 1,055 | 1,202 | The level of @OBJECT$ was observed to decrease @PREDICAT$ serum and @SUBJECT$ and that of thrombin, plasmin and urokinase exhibited variations. |
Fact | preserve | 223-270 | 233-237 | T31 | proteases such as angiotensin converting enzyme | ISA | 223 | 270 | preserve | 313-322 | 313-322 | T19 | urokinase | AminoAcidPeptideOrProtein | 313 | 322 | preserve | 223-232 | 223-232 | T15 | proteases | AminoAcidPeptideOrProtein | 223 | 232 | A28 | This study was designed to investigate the alterations in the levels of various proteases such as angiotensin converting enzyme (ACE), kallikrein, aminopeptidases, urokinase and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). | 137-519 | 137 | 519 | This study was designed to investigate the alterations in the levels of various @OBJECT$ @PREDICAT$ (ACE), kallikrein, aminopeptidases, @SUBJECT$ and plasmin in serum-heart and kidney and to find out whether the changes in the levels of these enzymes could explain the pathogeneses of hypertension induced by Dexamethasone (Dex). |
Fact | preserve | 1023-1025 | 1023-1025 | T71 | in | LOCATION_OF | 1,023 | 1,025 | preserve | 1026-1031 | 1026-1031 | T66 | serum | BodySubstance | 1,026 | 1,031 | preserve | 945-963 | 945-963 | T64 | carboxypeptidase-N | AminoAcidPeptideOrProtein | 945 | 963 | A29 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of enzymes such as angiotensin converting enzyme, @OBJECT$ and leucine aminopeptidase were found to be elevated @PREDICAT$ @SUBJECT$ as well as in tissues. |
Fact | preserve | 898-943 | 906-910 | T68 | enzymes such as angiotensin converting enzyme | ISA | 898 | 943 | preserve | 968-996 | 982-996 | T65 | leucine aminopeptidase | AminoAcidPeptideOrProtein | 968 | 996 | preserve | 898-905 | 898-905 | T62 | enzymes | Enzyme | 898 | 905 | A30 | The levels of enzymes such as angiotensin converting enzyme, carboxypeptidase-N and leucine aminopeptidase were found to be elevated in serum as well as in tissues. | 878-1054 | 878 | 1,054 | The levels of @OBJECT$ @PREDICAT$ , carboxypeptidase-N and @SUBJECT$ were found to be elevated in serum as well as in tissues. |
Fact | preserve | 1101-1168 | 1159-1168 | T83 | dihydroergotamine or triptans may be the first-step treatment | ISA | 1,101 | 1,168 | preserve | 1128-1136 | 1128-1136 | T72 | triptans | OrganicChemical | 1,128 | 1,136 | preserve | 1159-1168 | 1159-1168 | T75 | treatment | TherapeuticOrPreventiveProcedure | 1,159 | 1,168 | A2 | In a stratified approach, dihydroergotamine or triptans may be the first-step treatment for patients who present with a history of severe migraines that have responded poorly to previous treatments. | 1075-1285 | 1,075 | 1,285 | In a stratified approach, @PREDICAT$ @SUBJECT$ may be the first-step @OBJECT$ for patients who present with a history of severe migraines that have responded poorly to previous treatments. |
Fact | preserve | 1159-1168 | 1159-1168 | T85 | treatment | TREATS | 1,159 | 1,168 | preserve | 1128-1136 | 1128-1136 | T72 | triptans | OrganicChemical | 1,128 | 1,136 | preserve | 1173-1181 | 1173-1181 | T76 | patients | PatientOrDisabledGroup | 1,173 | 1,181 | A3 | In a stratified approach, dihydroergotamine or triptans may be the first-step treatment for patients who present with a history of severe migraines that have responded poorly to previous treatments. | 1075-1285 | 1,075 | 1,285 | In a stratified approach, dihydroergotamine or @SUBJECT$ may be the first-step @PREDICAT$ for @OBJECT$ who present with a history of severe migraines that have responded poorly to previous treatments. |
Fact | preserve | 1578-1591 | 1586-1591 | T118 | triptan drugs | ISA | 1,578 | 1,591 | preserve | 1578-1585 | 1578-1585 | T108 | triptan | OrganicChemical | 1,578 | 1,585 | preserve | 1586-1591 | 1586-1591 | T109 | drugs | PharmacologicSubstance | 1,586 | 1,591 | A4 | Among triptan drugs that are administered orally, the relative time to onset may be shorter with rizatriptan than sumatriptan. | 1572-1710 | 1,572 | 1,710 | Among @SUBJECT$ @PREDICAT$ @OBJECT$ that are administered orally, the relative time to onset may be shorter with rizatriptan than sumatriptan. |
Fact | preserve | 1286-1319 | 1312-1319 | T98 | Sumatriptan was the first triptan | ISA | 1,286 | 1,319 | preserve | 1286-1297 | 1286-1297 | T87 | Sumatriptan | OrganicChemical | 1,286 | 1,297 | preserve | 1312-1319 | 1312-1319 | T89 | triptan | OrganicChemical | 1,312 | 1,319 | A5 | Sumatriptan was the first triptan approved for the symptomatic treatment of migraine headache; newer triptans include zolmitriptan, naratriptan, and rizatriptan. | 1286-1459 | 1,286 | 1,459 | @SUBJECT$ @PREDICAT$ @OBJECT$ approved for the symptomatic treatment of migraine headache; newer triptans include zolmitriptan, naratriptan, and rizatriptan. |
Fact | preserve | 594-603 | 594-603 | T40 | treatment | TREATS | 594 | 603 | preserve | 548-554 | 548-554 | T34 | NSAIDs | PharmacologicSubstance | 548 | 554 | preserve | 630-648 | 639-648 | T39 | migraine headaches | DiseaseOrSyndrome | 630 | 648 | A6 | In the stepped-care approach, simple analgesics and NSAIDs are the recommended first step for the treatment of mild-to-moderate migraine headaches. | 490-649 | 490 | 649 | In the stepped-care approach, simple analgesics and @SUBJECT$ are the recommended first step for the @PREDICAT$ of mild-to-moderate @OBJECT$ . |
Fact | preserve | 1101-1168 | 1159-1168 | T83 | dihydroergotamine or triptans may be the first-step treatment | ISA | 1,101 | 1,168 | preserve | 1101-1118 | 1101-1118 | T71 | dihydroergotamine | OrganicChemical | 1,101 | 1,118 | preserve | 1159-1168 | 1159-1168 | T75 | treatment | TherapeuticOrPreventiveProcedure | 1,159 | 1,168 | A7 | In a stratified approach, dihydroergotamine or triptans may be the first-step treatment for patients who present with a history of severe migraines that have responded poorly to previous treatments. | 1075-1285 | 1,075 | 1,285 | In a stratified approach, @SUBJECT$ @PREDICAT$ @OBJECT$ for patients who present with a history of severe migraines that have responded poorly to previous treatments. |
Probable | preserve | 867-876 | 867-876 | T61 | treatment | TREATS | 867 | 876 | preserve | 812-827 | 812-827 | T53 | Corticosteroids | Hormone | 812 | 827 | preserve | 880-888 | 880-888 | T56 | patients | PatientOrDisabledGroup | 880 | 888 | A8 | Corticosteroids or opiates may be used as rescue treatment in patients who do not respond to second-step treatment. | 812-933 | 812 | 933 | @SUBJECT$ or opiates may be used as rescue @PREDICAT$ in @OBJECT$ who do not respond to second-step treatment. |
Fact | preserve | 318-366 | 361-366 | T28 | analgesics, nonsteroidal anti-inflammatory drugs | ISA | 318 | 366 | preserve | 330-366 | 361-366 | T20 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 330 | 366 | preserve | 318-328 | 318-328 | T19 | analgesics | PharmacologicSubstance | 318 | 328 | A9 | A wide variety of agents are available for the symptomatic treatment of migraine headache, including over-the-counter analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), combination products, opiates, ergot alkaloids, corticosteroids, dopamine antagonists, and triptans. | 188-489 | 188 | 489 | A wide variety of agents are available for the symptomatic treatment of migraine headache, including over-the-counter @OBJECT$ @PREDICAT$ @SUBJECT$ (NSAIDs), combination products, opiates, ergot alkaloids, corticosteroids, dopamine antagonists, and triptans. |
Fact | preserve | 253-262 | 253-262 | T29 | treatment | TREATS | 253 | 262 | preserve | 330-366 | 361-366 | T20 | nonsteroidal anti-inflammatory drugs | PharmacologicSubstance | 330 | 366 | preserve | 266-283 | 275-283 | T17 | migraine headache | DiseaseOrSyndrome | 266 | 283 | A13 | A wide variety of agents are available for the symptomatic treatment of migraine headache, including over-the-counter analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), combination products, opiates, ergot alkaloids, corticosteroids, dopamine antagonists, and triptans. | 188-489 | 188 | 489 | A wide variety of agents are available for the symptomatic @PREDICAT$ of @OBJECT$ , including over-the-counter analgesics, @SUBJECT$ (NSAIDs), combination products, opiates, ergot alkaloids, corticosteroids, dopamine antagonists, and triptans. |
Fact | preserve | 1159-1168 | 1159-1168 | T85 | treatment | TREATS | 1,159 | 1,168 | preserve | 1101-1118 | 1101-1118 | T71 | dihydroergotamine | OrganicChemical | 1,101 | 1,118 | preserve | 1173-1181 | 1173-1181 | T76 | patients | PatientOrDisabledGroup | 1,173 | 1,181 | A14 | In a stratified approach, dihydroergotamine or triptans may be the first-step treatment for patients who present with a history of severe migraines that have responded poorly to previous treatments. | 1075-1285 | 1,075 | 1,285 | In a stratified approach, @SUBJECT$ or triptans may be the first-step @PREDICAT$ for @OBJECT$ who present with a history of severe migraines that have responded poorly to previous treatments. |
Fact | preserve | 594-603 | 594-603 | T40 | treatment | TREATS | 594 | 603 | preserve | 533-543 | 533-543 | T33 | analgesics | PharmacologicSubstance | 533 | 543 | preserve | 630-648 | 639-648 | T39 | migraine headaches | DiseaseOrSyndrome | 630 | 648 | A15 | In the stepped-care approach, simple analgesics and NSAIDs are the recommended first step for the treatment of mild-to-moderate migraine headaches. | 490-649 | 490 | 649 | In the stepped-care approach, simple @SUBJECT$ and NSAIDs are the recommended first step for the @PREDICAT$ of mild-to-moderate @OBJECT$ . |
Probable | preserve | 1810-1817 | 1810-1817 | T101 | control | TREATS | 1,810 | 1,817 | preserve | 1776-1784 | 1776-1784 | T98 | exercise | DailyOrRecreationalActivity | 1,776 | 1,784 | preserve | 1828-1840 | 1828-1840 | T100 | hypertension | DiseaseOrSyndrome | 1,828 | 1,840 | A1 | Therefore bouts of mild to moderate intensity exercise may be beneficial in the control of hypertension. | 1724-1841 | 1,724 | 1,841 | Therefore bouts of mild to moderate intensity @SUBJECT$ may be beneficial in the @PREDICAT$ of @OBJECT$ . |